The Department of Medical Sciences of the RAS, Therapeutic Sciences Council meeting: Scientific projects marathon of Russian therapeutic departments "From innovative technologies and education to healthcare practice. Gut microbiota: clinical aspects"

Council for Therapeutic Sciences of the Russian Academy of Sciences, intestinal microbiota

1. Boccio JR, Iyengar V. Iron deficiency: causes, consequences, and strategies to overcome this nutritional problem. Biol Trace Elem Res. 2003;94(1):1-32. doi:10.1385/BTER:94:1:1.

2. Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013;3(7):a011866. doi:10.1101/cshperspect.a011866.

3. Cammarota G, Ianiro G, Bibbò S, et al. Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation? Intern Emerg Med. 2014;9(4):365-73. doi:10.1007/s11739-014-1069-4.

4. Gabbianelli R, Damiani E. Epigenetics and neurodegeneration: role of early-life nutrition. J Nutr Biochem. 2018;57:1-13. doi:10.1016/j.jnutbio.2018.01.014.

5. Kim YS, Unno T, Kim BY, et al. Sex Differences in Gut Microbiota. World J Mens Health. 2020;38(1):48-60. doi:10.5534/wjmh. 190009.

6. Ursell LK, Metcalf JL, Parfrey LW, et al. Defining the human microbiome. Nutr Rev. 2012;70 Suppl 1(Suppl 1):S38-44. doi:10.1111/j.1753-4887.2012.00493.x.

7. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1): 202-9. doi:10.1016/j.jhep.2020.03.039.

8. Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-17.e28. doi:10.1016/j.cgh.2021.12.002.

9. Yang S, Cheng J, Zhang R, et al. Metabolic dysfunctionassociated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol Res. 2022;52(2):176-86. doi:10.1111/hepr.13728.

10. Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5): 279-97. doi:10.1038/s41575-020-0269-9.

11. Martín-Mateos R, Albillos A. The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Front Immunol. 2021;12:660179.

12. Vallianou N, Christodoulatos GS, Karampela I, et al. Understanding the Role of the Gut Microbiome and Microbial Metabolites in NonAlcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules. 2021;12(1):56. doi:10.3390/biom12010056.

13. Sevcikova A, Izoldova N, Stevurkova V, et al. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy. Int. J. Mol. Sci. 2022;23: 488-517. doi:10.3390/ijms23010488.

14. Kozhevnikov AA, Raskina КV, Martynova EYu, et al. The relationship between the gut microbiota and human diseases, and the transplantation of microbiota as a way to restore its normal composition. RMJ. 2017;1(2):92-8. (In Russ.)

15. Xu H, Cao C, Ren Y, et al. Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment. Front Immunol. 2022;13:949490. doi:10.3389/fimmu.2022.949490.

16. Malard F, Vekhoff A, Lapusan S, et al. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nat Commun. 2021;12(1):3084. doi:10.1038/s41467-02123376-6.